Article Figures & Data
Figures
- Figure 1.
PD-L1 expression by sex, affected side, tumor grade, and age. There was no significant difference of PD-L1 positivity between (A) male and female, (B) renal pelvis and ureter, (C) low and high grade, and (D) age <70 and ≥70.
- Figure 2.
The positive incidence of androgen receptor expression by affected side renal pelvis or ureter and sex. (A) The positive incidence of androgen receptor (AR) expression in ureteral cancer cells was significantly higher than that in renal pelvis cancer cells (p=0.0445). (B) The positive incidence of AR expression on cancer cells in males tended to be higher than that in females (p=0.0715). Fisher’s exact test was performed to evaluate the association between localization of the primary tumor and the expression status of AR. AR: Androgen receptor.
- Figure 3.
Correlation of the expression level of androgen receptor and PD-L1 in upper urinary tract urothelial carcinoma. Androgen receptor (AR)-negative patients had significantly higher PD-L1 expression levels (mean value; 4.70%) compared with AR-positive group (mean value; 2.55%) (p=0.0324). AR: Androgen receptor.
- Figure 4.
Kaplan-Meier curves for cancer-specific survival stratified by the status of androgen receptor and PD-L1 expression. Among patients with androgen receptor (AR)+ tumors, negative PD-L1 expression was significantly associated with shorter cancer specific survival compared to those with positive PD-L1 expression (p=0.0493). On the other hand, PD-L1 expression in patients with AR-tumors had no significant prognostic impact (p=0.920). Differences between the two groups were assessed using the log-rank test. AR: Androgen receptor.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.